Plus Therapeutics Inc (PSTV)

$1.36

Market is closed - opens 8 PM, 06 Nov 2024

Performance

  • $1.33
    $1.45
    $1.36
    downward going graph

    2.21%

    Downside

    Day's Volatility :8.28%

    Upside

    6.21%

    downward going graph
  • $1.15
    $2.78
    $1.36
    downward going graph

    15.81%

    Downside

    52 Weeks Volatility :58.81%

    Upside

    51.08%

    downward going graph

Returns

PeriodPlus Therapeutics IncIndex (Russel 2000)
3 Months
-15.0%
0.0%
6 Months
-32.34%
0.0%
1 Year
-15.26%
0.0%
3 Years
-95.02%
-27.4%

Highlights

Market Capitalization
8.0M
Book Value
-$1.34
Earnings Per Share (EPS)
-3.09
Wall Street Target Price
42.33
Profit Margin
-240.15%
Operating Margin TTM
-289.05%
Return On Assets TTM
-69.39%
Return On Equity TTM
-522.5%
Revenue TTM
5.5M
Revenue Per Share TTM
1.19
Quarterly Revenue Growth YOY
-31.0%
Gross Profit TTM
-9.5M
EBITDA
-13.5M
Diluted Eps TTM
-3.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.23
EPS Estimate Next Year
-2.06
EPS Estimate Current Quarter
-0.53
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Plus Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3012.5%

Current $1.36
Target $42.33

Technicals Summary

Sell

Neutral

Buy

Plus Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Plus Therapeutics Inc
Plus Therapeutics Inc
-3.55%
-32.34%
-15.26%
-95.02%
-96.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-16.73%
-13.48%
-0.36%
33.18%
155.61%
Biontech Se
Biontech Se
-8.7%
18.88%
11.29%
-54.26%
538.49%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-0.55%
75.43%
58.71%
41.13%
193.04%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.43%
24.19%
29.58%
160.04%
155.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Plus Therapeutics Inc
Plus Therapeutics Inc
NA
NA
NA
-2.23
-5.22
-0.69
NA
-1.34
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.49
1.21
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.8
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.18
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.16
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Plus Therapeutics Inc
Plus Therapeutics Inc
Buy
$8.0M
-96.32%
NA
-240.15%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
155.61%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
538.49%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
193.04%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
155.08%
32.84
-4.74%

Insights on Plus Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.67M → 1.27M (in $), with an average decrease of 23.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -3.81M → -2.94M (in $), with an average increase of 13.9% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.7% return, outperforming this stock by 74.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 41.7% return, outperforming this stock by 136.7%

Institutional Holdings

  • AIGH Capital Management, LLC

    9.64%
  • Geode Capital Management, LLC

    0.79%
  • Vanguard Group Inc

    0.55%
  • Citadel Advisors Llc

    0.31%
  • BlackRock Inc

    0.12%
  • Tower Research Capital LLC

    0.07%

Company Information

plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.

Organization
Plus Therapeutics Inc
Employees
20
CEO
Dr. Marc H. Hedrick M.B.A., M.D.
Industry
Health Technology

FAQs